Navigation Links
Zogenix Secures $35 Million Debt Facility and Raises $15 Million Investment Capital
Date:7/13/2010

SAN DIEGO, July 13 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, announced that it has secured a $35 million debt facility led by Oxford Finance Corporation which also included Silicon Valley Bank.  The facility consists of a $25 million term loan and a $10 million revolving line of credit.  Concurrently, all existing Zogenix investors, including Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Abingworth Management, and Chicago Growth Partners, have provided an additional $15 million investment.

The financing will be used to satisfy working capital needs in the commercial launch of SUMAVEL™ DosePro™ (sumatriptan injection) needle-free delivery system, the company's first FDA-approved product, and the ongoing Phase 3 clinical development program of ZX002, a novel oral controlled-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain.  Proceeds will also be used to fully repay the outstanding balance of an existing term loan.

"This funding enhances our financial strength as we continue to focus on the successful launch of our first product, SUMAVEL DosePro," said Ann Rhoads, chief financial officer at Zogenix.  "The additional support from our investors represents their commitment to the growth of our company and the development of our pipeline."

"Oxford is pleased to participate in the financing package Zogenix has secured to further the growth of its company," said Chris Herr, managing director of Oxford Finance Corporation. "Zogenix has a strong management team that is leading their FDA-approved product to commercial success."

"The financing we are providing Zogenix will offer the flexibility the company needs to continue to meet its strategic objectives," said Michael White, senior relationship manager, Life Sciences, from Silicon Valley Bank in San Diego. "We are pleased to help Zogenix and many other life science companies in the San Diego market meet their goals."

About Zogenix

Zogenix, Inc., with offices in Emeryville and San Diego, Calif., is a privately held pharmaceutical company focused on the development and commercialization of medicines to treat neuroscience disorders and pain. The company is commercially focused on SUMAVEL™ DosePro™ (sumatriptan injection) needle-free delivery system, which launched in January 2010, for the acute treatment of migraine and cluster headache. The company's pipeline includes ZX002, a novel oral controlled-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain, which entered Phase 3 clinical trials in March 2010.  Zogenix also plans to license the patented DosePro needle-free drug delivery system to other companies. For additional information, please visit www.zogenix.com.

About Oxford Finance Corporation

A subsidiary of Sumitomo Corporation, Oxford is a specialty finance firm providing senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1.5 billion in loans, with lines of credit ranging from $500 thousand to $40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California and Massachusetts. For more information visit www.oxfordfinance.com.

About Silicon Valley Bank

Silicon Valley Bank (SVB) is the premier commercial bank for companies in the technology, life science, venture capital, private equity and premium wine industries. SVB provides a comprehensive suite of financing solutions, treasury management, corporate investment and international banking services to its clients worldwide. Through its focus on specialized markets and extensive knowledge of the people and business issues driving them, Silicon Valley Bank provides a level of service and partnership that measurably impacts its clients' success. Founded in 1983 and headquartered in Santa Clara, Calif., the company serves clients around the world through 26 US offices and international operations in China, India, Israel and the United Kingdom. Silicon Valley Bank is a member of global financial services firm SVB Financial Group (Nasdaq: SIVB) and a member of the FDIC and the Federal Reserve System. More information on the company can be found at www.svb.com.

SUMAVEL and DosePro are trademarks of Zogenix, Inc.


'/>"/>
SOURCE Zogenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone
2. DURECT Corporation Secures $50 Million Committed Equity Financing Facility
3. ProUroCare Medical Secures $885,000 in Financing
4. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
5. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
6. Logical Therapeutics Secures $16.9M Series C Financing Round
7. Breathe Technologies Secures $23 Million in Series C Financing
8. Johnson Controls Secures Global Facilities Management Win With GlaxoSmithKline
9. NxStage(R) Secures $15 Million Revolving Line of Credit
10. TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers
11. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Health, Inc. (Nasdaq: GHDX ) today reported financial results ... 2015. --> --> Revenue was ... million in the fourth quarter of 2014, an increase of 8 ... with the same period in the prior year. ... the fourth quarter of 2015, an increase of 9 percent compared ...
(Date:2/10/2016)... LEXINGTON, Massachusetts , February 10, 2016 --> ... Japan .  --> Japan .  ... Japan .  With submission, Shire continues to ... --> With submission, Shire continues to ... With submission, Shire continues to strengthen ...
(Date:2/10/2016)... and SAN DIEGO , Feb. ... a global leader in viral gene therapy manufacturing, and ... for congestive heart failure and other chronic diseases, have ... scalable manufacturing process and produce cGMP-grade RT-100 (Ad5.hAC6) Drug ... --> --> This ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Ongoing news ... Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer look ... released today illustrates the prevalence and causes of TBI among the aging population, and ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a ... for the fourth quarter and full year ended December 31, 2015 on Monday, February ... and webcast for the investment community following the release at 4:30 PM ET. Investors ...
(Date:2/10/2016)... ... ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves with age, ... Guide to Brain Training" by award-winning author Phyllis Strupp explains how brain ... 16, 2016. A free review copy is available to the media at NetGalley ...
(Date:2/10/2016)... ... 2016 , ... IDEX Health & Science, LLC announces the ... columns combine the strength of traditional stainless steel with the chemical inertness of ... operating at ultra-high pressures of 20,000 psi. The higher operating pressures allow faster ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... The recreational ... cannabis enthusiasts in the state still face a lot of restrictions as to where ... is intended for private, personal use” and that cannabis “may not be consumed openly ...
Breaking Medicine News(10 mins):